ATAI Investor Presentation Deck
April 2023, 30 slides
  1. ATAI
  2. Related Decks
  3. Investor Presentation Decks
company overview company overview march healing mental health disorders so that everyone everywhere can live a more life | ATAI
| ATAI
mental health disorders are one of the global health burdens most recently exacerbated by covid global market size in mental health was in and is expected to grow to by objective is to achieve clinically meaningful and sustained behavioral change in mental health patients by developing rapid acting and patient centric pharmaceutical and digital treatment solutions has multiple clinical stage drug development programs with focus on compound classes that all have prior evidence in humans portfolio approach to avoid binary risk and to optimize likelihood of success validation of operating model and ability to capture value of compass pathways in and licensing deal between and subsidiary perception in strong cash position of as of and access to up to an additional from term loan facility with lead to anticipated cash runway into life sciences healing everywhere can live a more life so everyone | ATAI
our objective achieve clinically meaningful and sustained change in patients diagnosed with mental health disorders key strategic pillars rapid acting intervention focus ongoing psychological support focus precision mental health focus and generation compounds with the potential to show strong plasticity rapid onset and more durable effect additional ongoing psychological care provided to patients before during and or after initial treatment interventions the identification of patient sub types using biological and digital achieving through combination | ATAI
our strategy will be delivered through a robust pipeline of drug development programs across several mental health indications with large unmet need | ATAI
achieved and expected milestones key achievements to date phase data phase data phase first subject dosed phase data phase a data phase data phase data phase data phase data phase data summer phase study data in cash as of plus access to up to an additional from term loan facility provides expected runway into we expect deliver several meaningful anticipated across our programs through with | ATAI
cognitive impairment associated with schizophrenia | ATAI
huge need for development lost life expectancy low treatment rate cognitive impairment is very common approvals for schizophrenia | ATAI
summary has previously shown pro cognitive effects in | ATAI
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show consistent clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated good tolerability | ATAI
scopolamine challenge in dogs scopolamine challenge in volunteers phase shows a consistent inverted shaped response curve across preclinical and clinical studies learning and memory a | ATAI
dose low doses enhanced learning and memory verbal learning delayed recall dose phase exploratory patients additionally a third party study in of also showed statistically significant positive cognitive signals | ATAI
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
anxiety | ATAI
massive unaddressed need gad patients in the us low treatment rate anxiety and depression are novel molecules approved in over a decade | ATAI
summary has the potential for like rapid onset efficacy with improved safety and tolerability | ATAI
sedation or dizziness confirms safety profile | ATAI
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase phase data dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action | ATAI
group average changes in beta power for low dose and high dose groups per time point average differences in each time point is compared to zero and time points with significant changes test were marked with asterisk phase data the effect was also time dependent showing a rapid onset of effect a delayed pharmacodynamic curve | ATAI
there is an unmet need in gad for therapies with rapid onset high efficacy and minimal side effects developed to address generalized anxiety disorder favorable safety | ATAI
depression | ATAI
urgent need for innovation inadequate response rate slow onset of treatment effect long term side effects novel therapies approved by in last decade depression | ATAI
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
pivotal phase trial designs pivotal study single dose randomization target topline data expected summer pivotal study fixed repeat dose randomization target topline data expected mid compass pathways is currently conducting a program composed of two trials which are to deliver by and | ATAI
may increase patient accessibility by reducing patient and clinic time commitment | ATAI
substance use disorder | ATAI
an ongoing pandemic number of sufferers in us high relapse rates drug overdose deaths increase limited treatment options for substance use disorder sud | ATAI
summary a single dose of showed potential for sustained reductions in cravings in dependent patients | ATAI
summary could potentially become a paradigm shifting therapy for use disorder current standard of care for is medication therapy requiring substitutes that carry significant side effects current strategies for withdrawal support have high rates of relapse has the potential to the first best in class treatment minimizing risk | ATAI
brand life sciences watching my best friend and business partner suffer being let down by existing treatments and finally finding comfort in therapies was all the inspiration i needed to commit my to this cause | ATAI
See More
ATAI
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Anxiety
Mental health
Recent decks by ATAI
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
March 2023
See all presentations by ATAI (13 decks)
Related decks
MindMed
Investor Presentation
April 2021
Neumora Therapeutics
IPO
September 2023
Talkspace
Results
February 2023
Avenue Therapeutics
IPO
October 2022
Talkspace
Investor Conference
January 2024
MindMed
Investor Presentation
September 2023
MindMed
Results
November 2023
Bionomics
Investor Presentation
June 2022
Recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
March 2023
MindMed
Investor Presentation
April 2021
Neumora Therapeutics
IPO
September 2023
Talkspace
Results
February 2023
Avenue Therapeutics
IPO
October 2022
Talkspace
Investor Conference
January 2024
MindMed
Investor Presentation
September 2023
MindMed
Results
November 2023
Bionomics
Investor Presentation
June 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io